RSH_KCR_CAIN457K2340

A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimliar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis.

Phase III
NCT03259074
All Other
Rheumatology
Kalpita Hatti, M.D.
Novartis
Cheryl Albin
  • Kadlec Clinic Rheumatology
  • Kadlec Research